Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound caincic acid suppository is a rectal pharmaceutical product developed by Xi'an Bohua Pharmaceutical Co., Ltd. for the treatment of hemorrhoids and anal fissures. The primary active ingredient, caincic acid (also known as cainca acid or cainca saponin), is a triterpenoid saponin traditionally derived from the roots of plants such as *Chiococca alba* (Cainca). It exhibits anti-inflammatory, analgesic, and anti-edema properties, which help to alleviate pain, pruritus, and swelling associated with symptomatic internal hemorrhoids and anal fissure-associated discomfort. The drug is formulated as a suppository for localized delivery and has been evaluated in randomized, double-blind, placebo-controlled Phase 2 clinical trials in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound caincic acid suppository.